(Total Views: 592)
Posted On: 09/21/2020 4:04:42 PM
Post# of 148908
Re: Evil Rabbit #57205
"I’d rather take $30+ now"
No one will be paying $21b for the company now without an approval in HIV AND outstanding proof-of-concept data (hard clinical endpoints OS/PFS, not biomarkers) in cancer and at least one autoimmune disease, because animal data mean shit.
And btw: huge deals only happen from a position of strength, not when you have 3 months of cash left, and just received a RTF.
That is why proposing and starting ever new indications without actually finishing one and delivering solid Phase 2 data is relatively meaningless mid-term. Had several years now to do GvHD to validate leronlimab in the autoimmune space, but failed to do so. Would have been a small study, but would have added massive value. Another blunder.
No one will be paying $21b for the company now without an approval in HIV AND outstanding proof-of-concept data (hard clinical endpoints OS/PFS, not biomarkers) in cancer and at least one autoimmune disease, because animal data mean shit.
And btw: huge deals only happen from a position of strength, not when you have 3 months of cash left, and just received a RTF.
That is why proposing and starting ever new indications without actually finishing one and delivering solid Phase 2 data is relatively meaningless mid-term. Had several years now to do GvHD to validate leronlimab in the autoimmune space, but failed to do so. Would have been a small study, but would have added massive value. Another blunder.
(15)
(1)Scroll down for more posts ▼
